PBH

Business Context and Reporting Period

Company: Prestige Consumer Healthcare Inc. (PBH)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 31, 2026
Business Overview: Prestige develops, manufactures, markets, and distributes over-the-counter (OTC) health and personal care products. Operations are conducted through two segments: North American OTC Healthcare (83.9% of revenue) and International OTC Healthcare (16.1% of revenue). The company relies heavily on third-party manufacturers for production and distributes through mass merchandisers, drug stores, and e-commerce channels.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 4.3% to $1,088.7 million. The North American segment declined 4.8%, primarily driven by a 20.6% drop in Eye & Ear Care sales due to supply shortages of Clear Eyes products. The International segment declined 1.5%.
• Margin Compression: Gross margin decreased to 54.7% from 55.8%, attributed to revenue decreases and costs related to the acquisition of a Canadian manufacturing facility. International gross margin dropped significantly to 54.1% from 58.1% due to inflation and product mix.
• Supplier Loan Write-off: The company recorded a $10.3 million write-off of a short-term loan to a supplier that discontinued operations. This was classified as "Other expense, net."
• Acquisitions: Completed the acquisition of Pillar5 Pharma Inc. (a sterile ophthalmic manufacturer) in December 2025 for approximately $110 million in net assets, adding $52.8 million to goodwill. Entered a definitive agreement to acquire the Breathe Right and Dimetapp brands from Foundation Consumer Brands, expected to close in fiscal 2027.
• Share Repurchases: Repurchased approximately 2.34 million shares of common stock for $156.3 million under its share repurchase program.

Guidance, Outlook, and Risks

Management Commentary & Outlook: Management expects economic conditions to remain volatile due to inflation, geopolitical conflicts, and supply chain constraints. The company anticipates that supply shortages, particularly in eye care products, will continue to negatively impact sales in the near term. The acquisition of Pillar5 is expected to improve long-term supply consistency for sterile eye care products. The company plans to fund the pending Foundation Consumer Brands acquisition through a new term loan and cash on hand.

Key Risks & Contingencies:

• Supply Chain Disruptions: Heavy reliance on third-party manufacturers (one supplier accounts for ~21% of gross revenue) creates vulnerability to production delays and price increases. Shortages of eye care products have already materially impacted results.
• Customer Concentration: Walmart and Amazon accounted for approximately 20% and 15% of gross revenues, respectively, in 2026. Loss of these customers or changes in their strategies could materially affect the business.
• Intangible Asset Impairment: Approximately 82% of total assets consist of goodwill and intangible assets. A 50-basis point increase in the weighted average cost of capital could result in a $16.6 million impairment charge for indefinite-lived intangibles.
• Debt Covenants: The company has $1.0 billion in senior notes and a revolving credit facility. While currently in compliance, restrictive covenants limit flexibility for dividends, additional debt, and acquisitions. Cross-default provisions exist across debt instruments.

Investor Verification Checklist

• Supply Chain Resolution: Verify the timeline and effectiveness of the Pillar5 acquisition in resolving Clear Eyes supply shortages and restoring Eye & Ear Care revenue growth.
• Customer Concentration: Monitor the stability of relationships with Walmart and Amazon, which collectively represent 35% of gross revenue.
• Debt Capacity: Assess the impact of the pending Foundation Consumer Brands acquisition on leverage ratios and compliance with debt covenants, given the potential increase in total indebtedness to ~$2.2 billion.
• Intangible Valuation: Review the sensitivity of goodwill and intangible asset valuations to changes in discount rates and terminal growth rates, given the high asset concentration in these categories.
• Supplier Solvency: Evaluate the risk of further supplier loan write-offs or disruptions given the recent $10.3 million loss and reliance on a limited number of third-party manufacturers.